| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
The aim of this study was to elucidate the predictive ability of cytokines, glycans, and circulating tumor DNA for the treatment effect of chemotherapies in patients with advanced hepatocellular carcinoma.
Predictive ability of cytokines were weak; however, serum angiopoietin2 level was closely related to overall survival of the patients. In addition, the level at progressive disease could determine the post progression survival. We also found out that serum levels of some glycans were correlated with the presence of the tumor and with overall survival. In examination of resected tumor, gene mutation related to cancer immortalization was found out to be the marker of short progression free survival and might be useful as the target of circulating tumor DNA.
|
